fbpx

Novartis Renews Commitment to Neglected Tropical Disease and Malaria Elimination, Investing USD 250 Million over Five Years to Research and Develop New Treatments 

Novartis Renews Commitment to Neglected Tropical Disease and Malaria Elimination, Investing USD 250 Million over Five Years to Research and Develop New Treatments 

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
Share on print
Print
  • Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five years   
  •  Commitment includes USD 100 million to advance R&D for Chagas disease, leishmaniasis, dengue, and cryptosporidiosis, and USD 150 million for next-generation antimalarials and a new formulation for babies under 5kg with malaria 
  •   Around the world, 1.7 billion people suffer from NTDs1, and there are 241 million cases of malaria2

BASEL, Switzerland, 23 June 2022,-/African Media Agency (AMA)/- Novartis endorses the Kigali Declaration on neglected tropical diseases (NTDs) and announces a five-year financial commitment of USD 250 million to the fight against NTDs and malaria in conjunction with the Kigali Summit on Malaria and NTDs alongside the 26th Commonwealth Heads of Government (CHOGM) meeting. This summit comes at a pivotal time for world leaders to reaffirm commitments to end neglected tropical diseases and malaria through the adoption of the Kigali Declaration. The declaration aims to mobilize political will and secure commitments to achieve the SDG3 target on NTDs and to deliver the targets set out in the World Health Organization’s Neglected Tropical Disease Roadmap (2021-2030). 

“Over the past decade, great progress has been made against NTDs, but there is still a lot more work to be done. Novartis will continue progressing our longstanding commitment to helping realize a world free of NTDs,” said Vas Narasimhan, CEO of Novartis. “Today, by endorsing the Kigali Declaration and pledging to invest USD 250 million, we aim to accelerate progress toward elimination of these diseases, which continue to cause suffering and stigma for millions of people around the globe.” 

Novartis was among the original endorsers of the London Declaration on NTDs in 2012, committing to a multidrug therapy (MDT) donation to support global efforts to eliminate leprosy. This was followed with a commitment of USD 100 million toward the fight against malaria at the Malaria Summit in London in 2018. By endorsing the Kigali Declaration today, Novartis reaffirms its commitment to the fight against NTDs and malaria. 

As part of the commitment over five years (2021-2025), Novartis will invest USD 250 million to advance research and development (R&D) of new treatments to combat NTDs and malaria. 

This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases. In collaboration with Welcome, the Novartis Institute for Tropical Diseases (NITD) is working to discover novel, curative antiparasitic therapies for Chagas disease. Further, we are collaborating with the Drugs for Neglected Diseases Initiative (DNDi), with earlier support from Wellcome, to jointly develop LXE408 for the treatment of visceral leishmaniasis, and are currently entering Phase II clinical development. We also made progress on a potential first-in-class compound to treat dengue fever, which is currently in Phase I clinical trial. Although this is the most common vector-borne viral disease in the world, there is currently no specific treatment for dengue. Cryptosporidium infection is the most prevalent form of parasitic diarrhea, a major cause of mortality among young children in developing countries. The NITD has discovered a promising drug candidate, EDI048, currently in Phase I clinical development. 

With regards to malaria, Novartis commits to investing USD 150 million to advance the clinical development programs of its three novel drug candidates to combat the emerging resistance 

to artemisinin. The company will also continue with activities to support the development of an optimized formulation for neonates and infants under 5kg, for whom no treatment currently exists. 

Around the world, 1.7 billion people suffer from NTDs, which are prevalent in tropical areas and mostly affect impoverished communities, causing devastating health, social and economic consequences. The NITD was established in 2001 within the Novartis Institutes for BioMedical Research (NIBR) to apply modern drug discovery technologies to finding new therapeutics for NTDs and malaria. 

Novartis has been committed to the fight against malaria for more than 20 years and to date, working with partners, the company has delivered more than 1 billion treatments, including more than 450 million pediatric treatments, without profit to malaria-endemic countries. According to the 2021 World Malaria Report, there were 241 million cases of malaria and 627,000 malaria deaths in 2020. Children under 5 are particularly at risk, and malaria takes the life of a child every minute in Africa. 

For more information on our work in NTDs: Novartis Institute for Tropical Diseases | Novartis 

For more information on our work in malaria: www.malaria.novartis.com

Distributed by African Media Agency (AMA) on behalf of Novartis.

About Novartis 

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world.

Find out more at https://www.novartis.com. 

Novartis is on Twitter. Sign up to follow @Novartis

For Novartis multimedia content, please visit https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact media.relations@novartis.com 

References

1. https://unitingtocombatntds.org/ntds/ 

2. https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2021 

Novartis Media Relations 

E-mail: media.relations@novartis.com 

Neil Henderson 

Novartis External Communications 

+41 79 361 28 69 | neil.henderson_ext@novartis.com 

Julie Masow 

Novartis US External Communications 

+1 862 579 8456 | julie.masow@novartis.com 

Arzum Ustun 

Novartis Global Health Communications 

+41 79 108 53 14 | arzum.ustun@novartis.com 

Paul Barasa 

Novartis Sub-Saharan Africa Communications

+254 71 970 3195 | paul.barasa@novartis.com 

Novartis Investor Relations 

Central investor relations line: +41 61 324 7944 

E-mail: investor.relations@novartis.com 

Central America 

Samir Shah +41 61 324 7944

Nicole Zinsli-Somm +4 16 132 43809

Isabella Zinck +41 61 324 7188

North America

Sloan Simpson +1 862 345 4440

Alina Levchuk +1 862 778 3372 

Parag Mahanti +1 973-876-4912 

You might also enjoy

Subscribe To Our Newsletter

Get updates and learn from the best

Become our partner

want more info, fill in this form.

Conférence de Presse en Ligne


Les frontières terrestres ne doivent pas constituer des obstacles à la dissémination de votre message. Grâce à notre service de conférence de presse en ligne, nous vous offrons l’opportunité de vous rapprocher des médias africains, chaque fois que vous en aurez besoin.

Nos services comprennent:

Digital Communications


Today, social networks constitute an organization’s first point of contact with a user and a potential customer. At first glance, you need to convince of the relevance and quality of your content to stimulate and motivate the user to go further. We create consistently inspiring online strategy to meet business objectives, engage stakeholders and enhance our client brand’s reputation internally and externally.

 

Communication​ digitale


Les réseaux sociaux représentent aujourd’hui le premier point de contact d’une organisation avec un utilisateur et un client potentiel. Au premier coup d’œil, vous devez le convaincre de la pertinence et de la qualité de votre contenu pour l’inciter à aller plus loin. Nous créons pour vous une stratégie de communication précise et adaptée sur les réseaux sociaux pour atteindre les objectifs commerciaux, impliquer les parties prenantes et améliorer la réputation de votre marque en interne et en externe.

Promotion​ d’événements


Le succès d’un événement réside en moitié dans sa promotion. Peu importe la beauté de l’événement, la qualité des orateurs et de l’ordre du jour, si personne ne rapporte ou ne parle de votre événement, vos efforts seront vains. Nous vous aidons à façonner votre récit et à créer un engouement autour de votre événement. De l’annonce de l’événement à la tenue de celui-ci, nous accompagnons votre effort de planification et le reflétons sur toutes les plateformes médiatiques.​

Formation​ Médiatique


Nous fournissons à vos porte-paroles les outils nécessaires pour présenter vos principaux messages et répondre avec confiance et cohérence aux questions. Notre formation est organisée soit à distance ou en présentiel, avec des études de cas réels et des répétitions. Nos clients repartent avec le sentiment d’être à l’aise devant les journalistes et d’agir en tant qu’ambassadeurs de la marque.

Veille​ Médiatique


Nous mesurons votre portée en relations publiques et rendons compte des informations de votre industrie et des activités de vos  concurrents en surveillant la majorité des canaux de diffusion dans toute l’Afrique. Une veille médiatique complète et opportune est essentielle pour s’assurer que vous ne manquez aucune référence à votre marque, que vous êtes constamment informé de ce qui se passe dans votre industrie et que vous êtes prêt à saisir les opportunités et à réduire les risques en temps opportun.

Relations​ Média


Peu importe le lieu où ils se trouvent, nous sommes une source d‘informations fiables pour les journalistes qui écrivent sur l’Afrique. Nous nous connaissons mutuellement et ils nous font confiance, car nous leur fournissons un contenu crédible qui les aide dans leurs tâches. Nous nous entretenons quotidiennement avec des journalistes aux quatre coins du continent, ce qui fait de nous l’un des organismes les plus efficaces pour mener des campagnes de relations avec les médias.

Stratégie et développement de contenu


Nous créons des stratégies de communication intelligentes, bien documentées et spécialisées destinées à vous aider à construire un récit fort qui engagera votre audience. Nous travaillons en synergie avec vous afin de rédiger des communiqués de presse et des articles d’opinions qui alimentent le récit de votre entreprise. Notre équipe a une expérience approfondie dans la création de récits et le développement de contenu multimédia.

DIFFUSION DE COMMUNIQUES​ DE PRESSE​


C’est le service phare d’AMA. Nous avons mis en place des canaux de diffusion des communiqués de presse auprès des journalistes des 54 États africains ainsi qu’auprès des journalistes américains et européens couvrant les sujets relatifs aux marchés émergents.​

​Nos services comprennent:​

Event Promotion


Half of the success of an event lays in its promotion. Doesn’t matter how beautiful the event is, how wonderful the speakers and the agenda are, if no one reports or talks about your event, your efforts are gone. We help you shape the narrative and create a drumbeat around your event. From the announce all the way to the outcome of the event, we accompany your planning effort and echo it through all media platforms

Media Training


We provide your spokespeople with the tools to present your key messages and answer questions with confidence and coherence. Our training is organised either remotely or face-to- face, with real case studies and rehearsals. Our clients leave feeling comfortable being in front of reporters and acting as brand ambassadors.

Media Monitoring


We measure and report on
your PR reach, industry news, and competitive activity by monitoring most channels in North, West, Central, East and Southern Africa. Comprehensive and timely media monitoring is critical to ensuring that you don’t miss any reporting of your brand,
you’re constantly informed on what’s going on around your business, and you’re ready to capitalise on opportunities and mitigate
risks in a timely fashion..

Media Relations


We have become an authoritative source of news for reporters writing about Africa, wherever they are. We know them, they know us, and they trust us for providing them with timely and accurate content that helps them do their job. We speak to reporters on a daily basis in all corners of the continent and this makes us one of the most effective agencies in running media relations campaigns.

Strategy & Content Development


We create smart and localised communications strategies to help build a strong narrative that will engage your audiences. We partner with you to create press releases and thought leadership pieces that sustain a drumbeat for your company’s narrative. Our team have deep experience in shaping narratives and developing media content.

PRESS RELEASE WIRE DISTRIBUTION

This is AMA’s flagship service. We have set up channels of distribution towards the journalists of the 54 African states, as well as to American journalists and European journalists covering emerging markets issues.
Our service includes:

Editorial advice

Localised editorial piece when needed

Distribution to the major print, broadcast and online publications along with industry-specific publications

Follow-up calls to secure interview request

Guaranteed distribution to Africa.com

Distribution to Bloomberg, LexisNexis and Thomson Reuters

Social Media Reach: Facebook, Twitter, LinkedIn, Instagram

Full online monitoring and print monitoring when available. Includesreadership stats and Advertising Value Equivalent

Translation in French, Arabic and Portuguese available